RxDoctor Payments Data

Nnamdi Dike, DO

Neurology · Carrollton, TXNPI 1306156401

Payments from drug & device makers

$28,228in general payments, 2019–2025

Across 1,334 payments — averaging $21.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • EMD Serono, Inc.$2K
  • Livanova USA, Inc.$2K
  • Teva Pharmaceuticals USA, Inc.$2K
  • Biogen$1K
  • UCB, Inc.$1K
  • plus $16K from 54 others

What the payments were for

  • Speaking & faculty fees$250%
  • Food & beverage$27,66198%
  • Education$5422%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)286$4,306
EMD Serono, Inc.41$1,695
Livanova USA, Inc.36$1,678
Teva Pharmaceuticals USA, Inc.57$1,528
Biogen66$1,320
UCB, Inc.61$1,264
Amgen(2 entities)44$1,222
SK Life Science, Inc.48$1,100
Lilly USA, LLC46$1,017
Lundbeck LLC42$881
Genentech USA, Inc.34$857
Pfizer63$844
Sanofi28$633
Sunovion Pharmaceuticals Inc.57$605
Avanir Pharmaceuticals, Inc.33$564
Neurocrine Biosciences, Inc.20$515
Aucta Pharmaceuticals, Inc.23$468
Ipsen Biopharmaceuticals, Inc15$449
Novartis20$405
Alnylam Pharmaceuticals Inc.19$395
AstraZeneca(2 entities)9$369
Argenx US, Inc.11$361
Eisai Inc.12$360
Neurelis, Inc.14$356
Biohaven Pharmaceuticals, Inc.20$353
Bristol Myers Squibb18$332
Grifols USA, LLC14$290
Jazz Pharmaceuticals Inc.5$232
Medtronic6$230
Biohaven Pharmaceutical Holding Company Ltd.15$230
Upsher-smith Laboratories LLC16$216
Otsuka America Pharmaceutical, Inc.12$213
Biotronik NRO, Inc.6$209
Arbor Pharmaceuticals, Inc.14$203
Supernus Pharmaceuticals, Inc.11$201
Abbott10$188
Averitas Pharma Inc.6$169
Scilex Pharmaceuticals Inc.10$162
GE HealthCare8$149
Acadia Pharmaceuticals Inc7$143
E.r. Squibb & Sons, L.L.C.2$124
Acorda Therapeutics, Inc5$120
Kyowa Kirin, Inc.4$86
Axsome Therapeutics, Inc.3$73
Johnson & Johnson4$71
Mallinckrodt Enterprises LLC3$70
Boston Scientific3$70
CSL Behring3$69
Amneal Pharmaceuticals LLC3$66
MDD US Operations, LLC3$65
Sumitomo Pharma America, Inc.3$56
Currax Pharmaceuticals LLC4$53
Octapharma USA, Inc.3$53
TG Therapeutics, Inc.2$49
Bausch Health US, LLC2$43
Xeris Pharmaceuticals, Inc.2$43
Tonix Medicines, Inc.2$39
Aprecia Pharmaceuticals, LLC2$38
Natus Medical Incorporated2$38
Akcea Therapeutics, Inc.1$35

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$28,228 in reported general payments places this provider in the 75th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$369,769
Medicare patients
355
Services billed
13,047

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5024$168,117
Gamunex-CImmune Globul G/Gly/Iga Avg 4624$101,664
NuedextaDextromethorphan Hbr/Quinidine14$36,112
Nurtec OdtRimegepant Sulfate20$31,094
BriviactBrivaracetam12$19,685
KeppraLevetiracetam13$5,623
Lacosamide28$3,152
Memantine Hcl74$1,909
Levetiracetam21$1,652
Diphenhydramine Hcl11$805
Primidone28$700
Gabapentin47$544
Pregabalin35$472
Divalproex Sodium14$468
Donepezil Hcl44$444

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Grifols USA, LLCGamunex-C$290$101,66424 claims
Avanir Pharmaceuticals, Inc.Nuedexta$564$36,11214 claims
PfizerNurtec Odt$844$31,09420 claims
UCB, Inc.Briviact$1,264$19,68512 claims
Upsher-smith Laboratories LLCTopiramate$216$15124 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,246 neurology providers in Texas.

Other neurology in Carrollton

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →